HUNTINGTON DISEASE
Clinical trials for HUNTINGTON DISEASE explained in plain language.
Never miss a new study
Get alerted when new HUNTINGTON DISEASE trials appear
Sign up with your email to follow new studies for HUNTINGTON DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Huntington's drug votoplam tested for Long-Term safety
Disease control OngoingThis study looks at the long-term safety and effects of the drug votoplam in people with Huntington's disease. About 144 participants who finished a previous votoplam study will continue treatment for up to 48 months. Researchers will monitor side effects and measure changes in b…
Matched conditions: HUNTINGTON DISEASE
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 00:47 UTC
-
New Huntington's drug enters early human testing
Disease control OngoingThis early-phase study tests an experimental drug called ER2001 in 27 adults with early-stage Huntington's disease. The main goal is to check safety and how the drug moves through the body. Participants receive either the drug or a placebo as an IV once a week for 6 weeks, with f…
Matched conditions: HUNTINGTON DISEASE
Phase: PHASE1, PHASE2 • Sponsor: ExoRNA Bioscience • Aim: Disease control
Last updated May 17, 2026 00:44 UTC
-
New pill aims to tackle Huntington's at its source
Disease control OngoingThis study tests an oral drug called SKY-0515 in 120 adults with Huntington's disease. The goal is to see if it can lower a harmful protein linked to the disease and improve symptoms. Participants take the drug or a placebo for a set period, and researchers monitor changes in pro…
Matched conditions: HUNTINGTON DISEASE
Phase: PHASE2, PHASE3 • Sponsor: Skyhawk Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 00:32 UTC
-
Gene therapy injection targets Huntington's disease in small trial
Disease control OngoingThis early-stage trial tests a gene therapy called AB-1001, injected directly into the brain, in 5 adults with early Huntington's disease. The main goal is to check safety and side effects, while also looking at brain changes on MRI. It is not a cure, but aims to slow or control …
Matched conditions: HUNTINGTON DISEASE
Phase: PHASE1, PHASE2 • Sponsor: AskBio France, SAS, a subsidiary of AskBio Inc. • Aim: Disease control
Last updated May 17, 2026 00:29 UTC
-
New Huntington's drug shows promise in early trial
Disease control OngoingThis study tests an experimental drug called tominersen in people with early-stage Huntington's disease. About 300 participants will receive either the drug or a placebo to see if it is safe and can slow the disease. The goal is to reduce harmful proteins in the brain and preserv…
Matched conditions: HUNTINGTON DISEASE
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New Huntington's drug shows promise in early safety trial
Disease control OngoingThis early study tests a new medicine, ER2001, given by IV for Huntington's disease. It includes 9 adults who already completed a previous ER2001 study. The main goal is to check safety and how the drug moves in the body, while also looking for any signs it might help control the…
Matched conditions: HUNTINGTON DISEASE
Phase: EARLY_PHASE1 • Sponsor: ExoRNA Bioscience • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Huntington's drug shows promise for speech and movement
Symptom relief OngoingThis study tests whether deutetrabenazine can help improve speech clarity and walking ability in people with Huntington disease. Researchers will measure how well participants can speak and move before and after taking the drug. The goal is to see if this medication can ease thes…
Matched conditions: HUNTINGTON DISEASE
Phase: PHASE2, PHASE3 • Sponsor: Vanderbilt University Medical Center • Aim: Symptom relief
Last updated May 17, 2026 00:30 UTC